SCHEMBL17290706

SCHEMBL17290706

COc1ccc(-c2c(C)[nH]n(C)c2=O)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
KMT2A Q03164 3/20 0.48
HTT P42858 2/20 0.48
DCTPP1 Q9H773 1/20 0.48
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
MAPT P10636 3/20 0.45
THRB P10828 1/20 0.45
TDP2 O95551 2/20 0.44
MAPK1 P28482 2/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43
TUBB8 Q3ZCM7 1/20 0.43
TUBA3E Q6PEY2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17295204 1.00 LMNA (0.48) LMNAKMT2AHTTDCTPP1KDM4E
SCHEMBL23400130 0.75 KDM4E (0.47) LMNAKMT2AHTTKDM4EALDH1A1
SCHEMBL29385001 0.73 KDM4E (0.55) LMNAKMT2AHTTKDM4EALDH1A1
SCHEMBL17290337 0.72 SLC11A2 (0.55) LMNAKMT2AHTTKDM4EALDH1A1
SCHEMBL23398840 0.72 GAA (0.64) LMNAKMT2AHTTDCTPP1KDM4E
SCHEMBL17290363 0.71 GAA (0.45) LMNAKMT2AHTTKDM4EALDH1A1
SCHEMBL10967427 0.69 KDM4E (0.54) KDM4EALDH1A1MAPTTHRBMAPK1
SCHEMBL8840880 0.68 PDE4A (0.67) LMNAKMT2AHTTKDM4EALDH1A1
SCHEMBL11292098 0.66 KDM4E (0.54) KDM4EALDH1A1PDE4ATSHRL3MBTL1
SCHEMBL30039574 0.66 KDM4E (0.50) LMNAKDM4EALDH1A1MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682938-B2 Pyrazolone derivatives as nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
EP-3148972-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS Cardioxyl Pharmaceuticals Inc. (US) 2017-04-05 EP disclosed
WO-2015183839-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-12-03 WO disclosed
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS THE JOHNS HOPKINS UNIVERSITY 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344437-A1 PYRAZOLONE DERIVATIVES AS NITROXYL DONORS TNNI3, PFKP, NOX5 LMNA 2480/4885KMT2A 4665/4885HTT 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.